Company Overview and News
Agilent Technologies, Inc. (A - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at A given that, according to its RSI reading of 29.35, it is now in oversold territory.
WFC WFCNP LRCX A ADBE
Investors interested in Electronics - Testing Equipment stocks are likely familiar with Teradyne (TER - Free Report) and Agilent Technologies (A - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
ACEA makes a range of real-time cell analysis and cytometer products, software, and consummables for life science research purposes.
NEWARK, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- SMART Global Holdings, Inc. (“SMART” or the “Company”) (NASDAQ: SGH), parent company of SMART Modular Technologies, Inc., today announced the appointment of Bryan Ingram, Senior Vice President and General Manager of the Wireless Semiconductor Division of Broadcom Inc., to its board of directors and its Compensation Committee, effective October 2, 2018.
A AVGO BRCM SGH
2018-10-01 seekingalpha - 1
ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhou, will be acquired by Agilent (NYSE: A) for $250 million in cash (see story). ACEA has developed the xCELLigence® cell therapy analysis device intended for academic and biopharma researchers. The device is used in immuno-oncology, pre-clinical drug discovery and basic academic research. In 2015, ACEA raised $30 million from China investors Qiming and Lilly Asia Ventures.
DMCAF A VSTM NVS WXXWY
Agilent Technologies said today it has acquires ACEA Biosciences for an undisclosed price, in a deal that expands the buyer’s offerings and presence in cell analysis technologies.
2018-09-25 globenewswire - 2
RUTHERFORD, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed a non-exclusive supply agreement with Agilent Technologies Inc. through which Agilent will manufacture Cancer Genetics’ proprietary FISH probe reagents.
Investors looking for stocks in the Electronics - Testing Equipment sector might want to consider either Teradyne (TER - Free Report) or Agilent Technologies (A - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
TER A EOG
The Zacks Electronics – Testing Equipment Industry comprises of companies offering advanced instruments, electronic testing equipment solutions, thermal management systems, electrical connectors, motors and various test solutions. The industry is currently benefiting from growing proliferation of electronic devices in every major sector, namely consumer, automobile, industrial, aerospace & defense, healthcare, semiconductors and communications.
TER A AME
Thermo Fisher Scientific Inc. shares TMO, -1.84% slid 1.9% Monday, after Goldman Sachs downgraded the stock to neutral from buy on valuation grounds. Goldman removed Thermo Fisher from its Americas Conviction List and added Agilent Technologies Inc. A, +0.50% which it now deems its top pick in life science tools and diagnostics. Agilent shares rose 0.5%. "We see this as an opportunistic time to make the switch to A given the set-up and valuation, with Agilent providing a rare Tools opportunity to own an accelerating growth story at a reasonable valuation with untapped capital allocation upside that could potentially be unlocked by the new CFO in our view," analysts wrote in a note.
Gilead took September's net gain "safer" Healthcare WallStar top spot. Its projected 21.82% net gain was 3% better than AbbVie's, and 29% more than Grifol's result, per analyst targets 9/10/18.
AMGN GRFS GILD A MCK ANTM SNY XRAY JNJ NVS ABBV PFE ABBV
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to A / Agilent Technologies, Inc. on message board site Silicon Investor.
as of ET